Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.
Peripheral Neuropathy|Antineoplastic Combined Chemotherapy Protocols
DRUG: Cesamet™ (nabilone)
The Average Pain Score at target site.
The Worst Pain Score at target site.|The Pain at Night Score at target site.|Quality of Life measures.|Patient satisfaction with treatment.|Safety will be assessed through the collection of AEs and vital signs.
To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain.

This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.